But should you
Exploring GLP-1 non-responder phenotypes provides insight
HOME | DIABETES EDUCATION | WEGOVY AND ULCERATIVE COLITIS: CAN IT MANAGE SYMPTOMS BETTER
Sobo can review symptoms, health history, medications, recovery goals, nutrition, labs when appropriate, and safety concerns to determine whether peptide therapy, rehabilitation, lifestyle support, or another medical step makes sense

Finally, note that while Tirzepatide is not yet FDA approved for weight loss, only for Type 2 Diabetes (though it seems that some healthcare practitioners may be prescribing it off label,) the FDA approval for Wegovy as a weight-loss drug predicates risk on body size (allowing prescriptions to people with a BMI 27 kg/m2 or greater who have at least one "weight-related comorbidity" or any patients with a BMI of 30.) So approval (based on a risk/benefit analysis) is based on fatness alone for some patients, and for others based on the idea that health conditions that people of all sizes get are "weight-related." This follows another dangerous pattern of weight -stigma in healthcare - viewing people as less-valuable and their lives more riskable at higher weights
The medication also affects the brains hunger and satiety signals